Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA3 | P32297 | 13/20 | 0.69 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.69 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.45 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2497766 | 0.95 | CHRNB2 (0.63) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 | |
| SCHEMBL2496710 | 0.92 | CHRNA3 (0.70) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 | |
| SCHEMBL6587133 | 0.92 | CHRNA3 (0.63) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 | |
| SCHEMBL6586979 | 0.92 | CHRNA3 (0.63) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 | |
| SCHEMBL14941891 | 0.91 | CHRNB2 (0.68) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 | |
| SCHEMBL14941878 | 0.91 | CHRNB2 (0.68) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 | |
| SCHEMBL2494032 | 0.87 | CHRNA3 (0.64) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 | |
| SCHEMBL6584907 | 0.86 | CHRNA3 (0.58) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 | |
| SCHEMBL12807443 | 0.86 | CHRNA3 (0.60) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 | |
| SCHEMBL14941778 | 0.86 | CHRNB2 (0.62) | CHRNA3CHRNB2CHRNA2CHRNB4CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNA3 20/4885CHRNB2 36/4885CHRNA2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.